Krishnan Suma: insider trades.
Krishnan Suma reported 13 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 13 sales ($9.0M), across 1 company.
- Transactions
- 13
- Purchases (P)
- 0
- Sales (S)
- 13
- Companies
- 1
- Name as filed
- Krishnan Suma
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Krystal Biotech, Inc. (KRYS) | Director, Officer, TenPercentOwner · President, R&D | 13 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-04 | Krystal Biotech, Inc. | S | 1,992 | $362.65 | 1,305,264 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 1,242 | $361.61 | 1,307,256 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 2,320 | $360.47 | 1,308,498 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 3,392 | $359.39 | 1,310,818 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 3,180 | $358.42 | 1,314,210 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 3,962 | $357.57 | 1,317,390 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 565 | $363.34 | 1,304,699 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 2,006 | $355.57 | 1,324,619 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 520 | $354.54 | 1,326,625 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 1,329 | $364.48 | 1,303,370 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 826 | $365.41 | 1,302,544 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 399 | $366.56 | 1,302,145 | Form 4 |
| 2026-09-04 | Krystal Biotech, Inc. | S | 3,267 | $356.37 | 1,321,352 | Form 4 |
Questions
What stock did Krishnan Suma buy or sell?
Krishnan Suma reported 13 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 13 sales ($9.0M), across 1 company.
Is Krishnan Suma the same person as other filers with this name?
This page covers SEC CIK 1298711 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/krishnan-suma-1298711.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.